Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the composition of the tumor microenvironment (TME). We dissected these influences in isocitrate dehydrogenase (IDH)-mutant gliomas by combining 14,226 single-cell RNA sequencing (RNA-seq) profiles from 16 patient samples with bulk RNA-seq profiles from 165 patient samples. Differences in bulk profiles between IDH-mutant astrocytoma and oligodendroglioma can be primarily explained by distinct TME and signature genetic events, whereas both tumor types share similar developmental hierarchies and lineages of glial differentiation. As tumor grade increases, we find enhanced proliferation of malignant cells, larger pools of undifferentiated glioma cel...
© 2022 Elsevier Inc.The factors driving therapy resistance in diffuse glioma remain poorly understoo...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
The isocitrate dehydrogenase (IDH) gene is recurrently mutated in adult diffuse gliomas. IDH-mutant ...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
© 2022 Elsevier Inc.The factors driving therapy resistance in diffuse glioma remain poorly understoo...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
The isocitrate dehydrogenase (IDH) gene is recurrently mutated in adult diffuse gliomas. IDH-mutant ...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
© 2022 Elsevier Inc.The factors driving therapy resistance in diffuse glioma remain poorly understoo...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...